PMID-25015963 – Thymosin-β4 prevents cardiac rupture and improves cardiac function in mice with MI
Peng H et al. "Thymosin-β4 prevents cardiac rupture and improves cardiac function in mice with myocardial infarction," American Journal of Physiology – Heart and Circulatory Physiology, 2014;307(5):H741-H751. doi:10.1152/ajpheart.00129.2014
Quick Reference
| Property | Value |
|---|---|
| PMID | 25015963 |
| DOI | 10.1152/ajpheart.00129.2014 |
| Year | 2014 |
| Journal | American Journal of Physiology – Heart and Circulatory Physiology |
| Study Type | Animal in vivo |
| Evidence Level | V |
| Sample | Mice with induced myocardial infarction |
| Peptide(s) Studied | TB-500 |
Key Findings
- Tβ4 treatment reduced mortality from post-MI cardiac rupture
- Decreased inflammatory cell infiltration in the infarcted myocardium
- Improved left ventricular function and reduced ventricular dilation
- Enhanced capillary density in damaged cardiac tissue (angiogenesis)
- Reduced myocyte apoptosis and collagen deposition (anti-fibrotic)
Study Design
Murine myocardial infarction model via coronary artery ligation. Tβ4 administered post-infarction. Outcomes: survival, cardiac function (echocardiography), histological analysis (inflammation, fibrosis, capillary density, apoptosis).
Limitations
- Mouse model; significant differences from human cardiac physiology
- Acute MI model may not reflect chronic ischemic cardiomyopathy
- Timing and dosing may not translate directly to human protocols
Clinical Relevance
Key preclinical study demonstrating Tβ4's cardioprotective potential. The prevention of cardiac rupture (a fatal complication of MI) and functional improvement are clinically meaningful endpoints. Published in a respected cardiovascular physiology journal. Supports the rationale for cardiac repair applications.
Related
#research #animal-in-vivo #evidence-level-V